Enterprise Compliance & Quality
Find out how MetricStream can help
Quality and Compliance for Pharmaceuticals
  FDA Compliance
21 CFR Part 11
cGMP / cGXP
Pharmaceutical
  Quality Management
Quality Audits
Corrective and Preventive Action
Enterprise Quality Management
ISO Compliance
Six Sigma
  Governance and Compliance
Sarbanes Oxley compliance
Regulatory compliance
Risk management/ Change control
  Manufacturing & Automobile Quality
Managing Automobile quality system
Manufacturing and Hi-Tech quality
Supplier quality management
Kick start your software evaluation process

 

For more information
Call us at +1-650-620-2967


Stay connected to the latest developments in:

FDA current Good Manufacturing Practices
Pharmaceuticals & Drug Manufacturers

Join a growing network of Quality and Compliance professionals. You will have access to:

  • Bayers, Johnson and Johnson, Glaxo, Ranbaxy on their implementation of Code of Federal Regulations (CFR)
  • FDA cGMP for the New Millennium Science & Risk based approach, FDA Regulations in the news
  • Emerging cGMP trends in Production & Process control, Laboratory Controls, Packaging & Labeling Controls, Records and Reports
  • Industry Good manufacturing Practices Human and veterinary pharmaceutical products 21 CFR 210-211
    Biological products -21 CFR 600 & 21 CFR 620
    Medical devices -21 CFR 820

Register FREE with the Quality and Compliance network. You have no obligations and you can choose to unsubscribe at anytime.

Register and receive a FREE e-book
get industry best practices into Regulatory Compliance issues.

Quality & ComplianceQuality & Compliance
This e-book is a collection of white papers covering a wide range of topics from best practices in Section 302 & 404 of Sarbanes-Oxley Act, FDA compliance, 21 CFR Part 11, Internal Audits, CAPA. This e-book distills basic design and framework for ensuring quality and compliance.

Name:*
Job Title:*
Business Email:*
Phone Number:* Ext:
Company Name:*
Country:*
Zip Code/Postal Code:*
Reason for visiting the site:*
Additional Comments:*